{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-133532","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2024-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.664065+00:00","generated_at":"2026-05-29T06:57:51.297429+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agenus strategic realignment: 60% annual cost cut, $100M cash burn target, workforce reduction","bullets":["Agenus will reduce annual expenditures by 60% and target a cash burn of $100 million for fiscal year 2025.","Workforce reduction with severance costs estimated at approximately $1.1 million; charges expected in Q1 2025.","Company will focus resources on lead program botensilimab/balstilimab (BOT/BAL) for MSS CRC and other cancers.","Agenus secured a $22M mortgage on real estate assets to support operational flexibility during restructuring."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-133532","json":"https://secwatch.observer/filing/0000950170-24-133532.json","markdown":"https://secwatch.observer/filing/0000950170-24-133532.md","text":"https://secwatch.observer/filing/0000950170-24-133532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024133532/0000950170-24-133532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024133532/agen-20241205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T06:57:51.297429+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5764f1c286dc7a4ed98ca1eff415a3c04cc7cb4e","claim":"AGENUS INC announced a restructuring with charges of approximately $1.1 million affecting Agenus Inc. (excluding its independently operating subsidiaries) (reducing its workforce).","evidence_excerpt":"Costs associated with the workforce reduction are primarily severance payments and are estimated at approximately $1.1 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024133532/0000950170-24-133532-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.1 million"},{"label":"Affected area","value":"Agenus Inc. (excluding its independently operating subsidiaries)"},{"label":"Headcount","value":"reducing its workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}